🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  2. Hydroxypropyl Guar Galactomannan

    Alcon Laboratories (Australia) Pty Ltd

    Dry Eye Disease

    phase 2 small molecule completed

    1 trial

  3. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  4. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  5. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Malignant Solid Tumor

    phase 2 small molecule active

    1 trial

  6. Immune Globulin Infusion (Human), 10% Solution

    Takeda

    Hematologic Malignancies

    phase 2 mab active

    1 trial

  7. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  8. Ixazomib

    Takeda

    Myeloid Hematologic Malignancy

    phase 2 small molecule completed

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Acasunlimab

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CISPLATIN , CARBOPLATIN

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  12. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  13. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  14. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  15. Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial

  16. Lurbinectedin 4 MG Injection [Zepzelca]

    Jazz Pharmaceuticals Ireland Limited

    Gastrointestinal Malignancies

    phase 2 small molecule completed

    1 trial

  17. METHYLPREDNISOLONE, METHYLPREDNISOLONE, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., GLUCOSE 5 % B.BRAUN, solution pour perfusion

    Pari Pharma GmbH

    Fulminant myocarditis

    phase 2 small molecule active

    1 trial

  18. MPH966

    Mereo BioPharma Group plc

    Hematologic Malignancy

    phase 2 small molecule terminated

    1 trial

  19. MR-130A-01

    Mylan Pharma UK

    Investigation of maintenance of ovulation inhibition after intentional application errors for indication of contraception in healthy subjects

    phase 2 small molecule active

    1 trial

  20. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Intrahepatic Cholestasis of Pregnancy

    phase 2 small molecule active

    1 trial

  21. Metformin

    United Therapeutics Europe Ltd

    Polycystic Kidney, Autosomal Dominant

    phase 2 small molecule completed

    1 trial

  22. Multivalent recombinant OspA Lyme Borreliosis Vaccine

    Takeda

    Prophylaxis of Lyme Borreliosis

    phase 2 mab completed

    1 trial

  23. NANOBODY® Placebo; The placebo is a standard placebo formulation containing common excipients for NANOBODY drug products and is used by Sanofi for NANOBODY clinical studies., SAR442970

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  24. NIVOLUMAB, BT5528

    BICYCLE THERAPEUTICS

    Advanced Malignancies Associated with EphA2 Expression

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources